Data Integrity and ALCOA+ Principles

Accuracy in Source Documentation: Guidelines for Clinical Sites

Posted on digi By digi

The final letter in the ALCOA acronym—Accurate—is perhaps the most vital when it comes to ensuring data credibility in clinical trials. Accuracy in source documentation means that data recorded reflects the true observation, measurement, or result, without error, omission, or misrepresentation. This principle is especially critical when documenting primary efficacy data, adverse events, dosing, and informed consent.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

Training Site Staff on ALCOA Principles

Posted on digi By digi

ALCOA—Attributable, Legible, Contemporaneous, Original, Accurate—is the foundational standard for ensuring data integrity in clinical trials. Regulatory bodies like the FDA and EMA expect all individuals involved in trial documentation to understand and apply these principles consistently. While sponsors and CROs carry oversight responsibilities, it is the clinical site staff who are directly responsible for capturing and maintaining trial data in a compliant manner.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

ALCOA Examples from Real Clinical Audits

Posted on digi By digi

ALCOA principles—Attributable, Legible, Contemporaneous, Original, Accurate—are not just theoretical standards. They are active audit checkpoints during GCP inspections by agencies like the FDA, EMA, and local regulatory authorities. Noncompliance with ALCOA is one of the most frequently cited findings in inspection reports worldwide.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

Role of ALCOA in Preventing Data Fraud

Posted on digi By digi

Data fraud in clinical trials refers to the deliberate falsification, fabrication, or manipulation of trial data. Whether through altered lab values, invented patient visits, or backdated records, fraud undermines trial integrity, jeopardizes patient safety, and can result in severe regulatory sanctions.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

ALCOA Checklist for Clinical Trial Monitors

Posted on digi By digi

Clinical Research Associates (CRAs) are the primary line of defense in ensuring that trial data is collected, documented, and verified in compliance with ALCOA principles—Attributable, Legible, Contemporaneous, Original, and Accurate. During site monitoring visits, it’s critical that CRAs are equipped not only with protocol and SOPs, but also with a structured tool to evaluate documentation quality.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

How to Implement ALCOA Principles in Clinical Data Management Systems

Posted on digi By digi

In modern clinical research, most data is captured, stored, and processed electronically. This transition from paper to digital records has made Clinical Data Management Systems (CDMS) central to ensuring data quality and integrity. To meet global regulatory expectations—including those of the FDA, EMA, and ICH E6(R2)—all electronic systems must comply with ALCOA principles.

Click to read the full article.

Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA), Data Integrity and ALCOA+ Principles

Ensuring Data Completeness in Decentralized Trials

Posted on digi By digi

As decentralized clinical trials (DCTs) become more mainstream, ensuring complete data collection has become a critical regulatory and operational challenge. With trial components distributed across digital platforms, home visits, wearable devices, and telehealth sessions, the risk of missing or incomplete data increases exponentially. According to ALCOA+ principles—where “Complete” is the first extension beyond the original ALCOA—all data relevant to the study must be recorded, including omissions, errors, deviations, and multiple attempts.

Click to read the full article.

Complete, Consistent, Enduring, and Available (ALCOA+), Data Integrity and ALCOA+ Principles

Consistency in Data Entry Across Multi-Site Trials

Posted on digi By digi

In multi-site clinical trials, data collection is distributed across locations, investigators, and time zones—yet the output must be unified, standardized, and reliable. The ALCOA+ principle of Consistency ensures that data is uniformly recorded regardless of the site, system, or staff involved.

Click to read the full article.

Complete, Consistent, Enduring, and Available (ALCOA+), Data Integrity and ALCOA+ Principles

How to Make Clinical Data Enduring and Immutable

Posted on digi By digi

In clinical research, data must not only be correct and complete—it must also be enduring. This means the data must be maintained intact and accessible for the entire required retention period, typically 15–25 years depending on local regulations and study type. According to ALCOA+, “Enduring” refers to preserving the integrity, readability, and usability of trial data over time.

Click to read the full article.

Complete, Consistent, Enduring, and Available (ALCOA+), Data Integrity and ALCOA+ Principles